Effect of clopidogrel on the hydroxylation and sulfoxidation of omeprazole: A single dose study in healthy human volunteers

Based upon the known potential interaction between omeprazole (OMP) and clopidogrel (CLOP), the current study was designed to evaluate the effect of CLOP on disposition of OMP and its two major metabolites, 5-hydroxyomeprazole (5-OH-OMP) and omeprazole sulfone (OMP-S) in healthy clinical subjects. A randomized, open label, 2-period, crossover study was designed. Twelve volunteers were selected, of whom eight were extensive metabolizers (EM) of CYP2C19 and 4 were poor metabolizers (PM). They received single dose of OMP either alone or in combination with CLOP (single dose) and samples were collected periodically to calculate various pharmacokinetic parameters. Changes in most of the pharmacokinetic parameters of OMP, 5-OH-OMP and OMP-S were insignificant (P ˃ 0.05) both in EM and PM except for the maximum concentration (Cmax) of 5-OH-OMP and OMP-S in EM. The OMP Cmax and AUC0-∞ was increased both in EM and PM after concomitant administration of OMP with CLOP. The 5-OH-OMP Cmax was decreased in both EM and PM, demonstrating that CLOP inhibits hydroxylation of OMP. The OMP-S Cmax and AUC0-∞ were increased both in EM and PM showing that CLOP may induce sulfoxidation of OMP. It was concluded that CLOP may inhibit hydroxylation of OMP to a greater extent in EM than in PM, leading to higher OMP Cmax and AUC0-∞. Furthermore, the sulfoxidation of OMP may also be induced by CLOP. So, it is suggested that both these drugs should be carefully prescribed together to avoid any harm to the patients. (Application number13/EC/Pharm. Ref number 12/Pharm).

• Publication year

  2017

• Venue

  EXCLI Journal : Experimental and Clinical Sciences

• Publication date

  2017-03-22

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.17179/excli2016-658PMID 28507476PMCID 5427475
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Should proton pump inhibitors be withheld from patients taking clopidogrel? The issue that has been giving me heartburn!

  2015cited by this paper
• Simple and Fast Liquid Chromatography–Mass Spectrometry (LC–MS) Method for the Determination of Omeprazole, 5-hydroxyomeprazole, and Omeprazole Sulphone in Human Plasma

  2015cited by this paper
• Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo‐Controlled, Crossover Comparison Studies

  2011cited by this paper
• Risk of Adverse Clinical Outcomes with Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Percutaneous Coronary Intervention

  2010cited by this paper
• Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study

  2010cited by this paper
• Drug–Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors

  2009cited by this paper
• Clopidogrel Inhibits CYP2C19‐Dependent Hydroxylation of Omeprazole Related to CYP2C19 Genetic Polymorphisms

  2009cited by this paper
• Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.

  2008cited by this paper
• Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects

  2007cited by this paper
• Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations

  2007cited by this paper
• Impact of P‐glycoprotein on clopidogrel absorption

  2006cited by this paper
• Possible Interethnic Differences in Omeprazole Pharmacokinetics

  2006influential reference
• Fexofenadine does not affect omeprazole pharmacokinetics: both are putative P-glycoprotein substrates.

  2004cited by this paper
• Concordance between clopidogrel use and prescribing guidelines

  2004cited by this paper
• Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance

  2004cited by this paper
• Omeprazole as a CYP2C19 Marker in Chinese Subjects: Assessment of Its Gene‐Dose Effect and Intrasubject Variability

  2004cited by this paper
• Proton pump inhibitors: an update.

  2002cited by this paper
• Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein

  2001cited by this paper
• Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors

  2000cited by this paper
• Clopidogrel bioavailability: absence of influence of food or antacids.

  1999cited by this paper
• Safety profile of the proton-pump inhibitors.

  1999cited by this paper
• Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.

  1996cited by this paper
• Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation.

  1993cited by this paper
• Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism.

  1993cited by this paper

• Self nano-emulsifying drug delivery system based delivery of ketamine for enhanced therapeutic efficacy through behavioral performance in animal model

  2026cites this paper
• A Phenotyping Tool for Seven Cytochrome P450 Enzymes and Two Transporters: Application to Examine the Effects of Clopidogrel and Gemfibrozil

  2025cites this paper
• Pharmacokinetics and pharmacodynamics analysis of XQ-1H and its combination therapy with clopidogrel on cerebral ischemic reperfusion injury in rats.

  2019cites this paper